Rhizen Pharmaceuticals AG, a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company, announced the release of data on its differentiated next-generation clinical-stage PARP (Poly ADP-Ribose Polymerase) and DHODH (DiHydro Orotate DeHydrogenase) inhibitor programs at the American Association for Cancer Research (AACR) 2022 Annual Meeting.
- Read more about Rhizen Pharmaceuticals AG Presents Data on Its Differentiated PARP and DHODH Inhibitor Programs at AACR 2022
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/rhizen-pharmaceuticals-ag-presents-data-on-its-differentiated-parp-and-dhodh-inhibitor-programs-at-aacr-2022
No comments:
Post a Comment